LY288513
LY288513 is a selective non-peptide CCK-B receptor antagonist with an IC50 value of 16 nM. LY288513 produces an anxiolytic-like action in mice.
For research use only. We do not sell to patients.
- CAS No.: 147523-65-7
- Formula: C22H18BrN3O2
- Molecular Weight:436.30
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-106840
L-365260CCK-B Antagonist -
HY-101352
LY 225910Cholecystokinin Receptor Antagonist -
HY-105226
CI-988CCK2R Antagonist -
HY-P1097
Gastrin I, humanCCK2 Agonist -
HY-106840R
L-365260 (Standard)Reference Standard -
HY-103355
YM022CCK-BR Antagonist -
![[Leu15]-Gastrin I (human)](https://file.medchemexpress.com/product_pic/hy-p2671.gif)
HY-P2671
[Leu15]-Gastrin I (human)Peptide Hormone -
HY-17617
NastorazepideCCK-2 Receptor Antagonist -
HY-103355R
YM022 (Standard)Reference Standard -
HY-129810
PD 135158CCKB Antagonist -
HY-17617R
Nastorazepide (Standard)CCK-2 Receptor Antagonist -
HY-118546
JNJ-17156516CCK1-receptor Antagonist
Biological Activity
Description
IC50 & Target
IC50: 16 nM (CCK-B receptor)[1]
In Vitro
LY288513 (10 nM; 2 days) suppresses the effects of CCK-8 on CD4+ T cell subset-specific transcription factors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CD4+ T cells
-
Concentration:10 nM
-
Incubation Time:2 days
-
Result:Suppressed the effects of CCK-8 on CD4+ T cell subset-specific transcription factors.
In Vivo
LY288513 (1000 mg/kg, p.o.) potentiates the effects of a CNS depressant, slightly lowered body temperature, and had modest sedative effects only at the highest dose examined[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CD-l mice[3]
-
Dosage:3, 10 mg/kg; 10, 30 mg/kg
-
Administration:I.p.; p.o.
-
Result:Displayed anxiolytic-like effects in the elevated plusmaze.
Chemical Information
-
CAS No. 147523-65-7
-
Molecular Weight 436.30
-
Formula C22H18BrN3O2
-
SMILES
O=C(N1NC([C@@H](C2=CC=CC=C2)[C@@H]1C3=CC=CC=C3)=O)NC4=CC=C(Br)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
[1]. Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann N Y Acad Sci. 1994 Mar 23;713:300-11. [Content Brief]
[2]. Zhang JG, et al. Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4(+) T cells in vitro. Int Immunopharmacol. 2014;20(2):307-315. [Content Brief]
[3]. Helton DR, et al. Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav. 1996 Mar;53(3):493-502. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LY288513 Related Classifications
HY-103357 Related Classifications
Powered by Bioz